- Hansen RB, Kavanaugh A. Certolizumab pegol for the treatment of psoriatic arthritis. Expert Rev Clin Immunol 2015;11 (3): 307–318.
- Jinesh S. Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs. Inflammopharmacology 2015;23 (2–3): 71–77.
- Sams WM Jr, Thorne EG, Small P, Mass MF, McIntosh RM, Stanford RE. Leukocytoclastic vasculitis. Arch Dermatol 1976;112 (2): 219–226.
- Tsai MH, Yang JH, Kung SL, Hsiao YP. Levamisole-induced myopathy and leukocytoclastic vasculitis: a case report and literature review. Dermatol Ther (Heidelb) 2013;26 (6): 476–480.
- Butts GT, Bishop PR, Wyatt JP, Nowicki MJ. Leukocytoclastic vasculitis in an adolescent with ulcerative colitis: report of a case and review of the literature. Sage Open Med Case Rep 2014;2: 2050313X14547609.
- Ekenstam EAF, Callen JP. Cutaneous leukocytoclastic vasculitis: clinical and laboratory features of 82 patients seen in private practice. Arch Dermatol 1984;120 (4): 484–489.
- Zax RH, Hodge SJ, Callen JP. Cutaneous leukocytoclastic vasculitis: serial histopathologic evaluation demonstrates the dynamic nature of the infiltrate. Arch Dermatol 1990;126 (1): 69–72.
- Bahrami S, Malone JC, Webb KG, Callen JP. Tissue eosinophilia as an indicator of drug-induced cutaneous small-vessel vasculitis. Arch Dermatol 2006;142 (2): 155–161.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 30, 2017 - Issue 2